NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
David S. Ettinger(Sidney Kimmel Comprehensive Cancer Center), Douglas E. Wood(Seattle Cancer Care Alliance), Charu Aggarwal(UPMC Hillman Cancer Center), Dara L. Aisner(University of Colorado Cancer Center), Wallace Akerley(University of Utah), Jessica R. Bauman(Fox Chase Cancer Center), Ankit Bharat(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Débora S. Bruno(Cleveland Clinic), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Lucian R. Chirieac(Dana-Farber Brigham Cancer Center), Thomas A. D’Amico(Cancer Institute (WIA)), Thomas J. Dilling(Moffitt Cancer Center), M.C. Dobelbower(University of Colorado Cancer Center), Scott Gettinger(Smilow Cancer Hospital), Ramaswamy Govindan(Barnes-Jewish Hospital), Matthew A. Gubens(UCSF Helen Diller Family Comprehensive Cancer Center), Mark Hennon, Leora Horn(Breast Cancer Research Foundation), Rudy P. Lackner(Susan Thompson Buffett Foundation), Michael Lanuti(Massachusetts General Hospital), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Jules Lin(University of Michigan), Billy W. Loo(Cancer Institute (WIA)), Renato Martins(Seattle Cancer Care Alliance), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sandip Pravin Patel(University of California San Diego), Karen L. Reckamp(City Of Hope National Medical Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Steven E. Schild, Theresa A. Shapiro(Sidney Kimmel Comprehensive Cancer Center), James Stevenson(Cleveland Clinic), Scott J. Swanson(Dana-Farber Brigham Cancer Center), Kurt W. Tauer(St. Jude Children's Research Hospital), Stephen C. Yang(Sidney Kimmel Comprehensive Cancer Center), Kristina M. Gregory(National Comprehensive Cancer Network), OCN(National Comprehensive Cancer Network), Miranda Hughes(National Comprehensive Cancer Network)
Cited by 1,003Open Access
Abstract
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."
Related Papers
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al.|New England Journal of Medicine|2016|10k
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al.|New England Journal of Medicine|2018|6.6k
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al.|New England Journal of Medicine|2017|5.2k
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al.|New England Journal of Medicine|2018|3.7k